Antibodies as Drugs: The Art in Antibody Engineering

May 5-8, 2024 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers: Laura M. Walker and Paul W. H. I. Parren

  In Person
  On Demand

May 5-8, 2024 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers: Laura M. Walker and Paul W. H. I. Parren

Important Deadlines
Early Registration Deadline: Mar. 5, 2024
Scholarship Deadline: Feb. 13, 2024
Short Talk Abstract Deadline:
Poster Abstract Deadline: Feb. 13, 2024
Meeting Summary

# Drug Discovery, Bioengineering and Digital
The deadline to submit an abstract for short talk and poster presentation consideration has passed. For any questions or issues, please email info@keystonesymposia.org.

Antibodies have become the most successful and versatile class of biological drugs with well over 100 therapeutic antibodies approved for human use. Antibody engineering for optimized and novel functionalities is providing unprecedented opportunities in our quest to develop innovative treatments for a wide variety of diseases. In recent years, engineered antibody formats have matured from research to clinical stage molecules with engineered antibodies currently representing about 40% of the 1,000+ antibodies in clinical development. This conference will review the translation of fundamental insights in both antibody and pathological mechanisms into next generation therapeutics and will discuss the opportunities and challenges ahead.

Unique Career Development Opportunities

This meeting will feature a Career Roundtable where trainees and early-career investigators will have the opportunity to interact with field leaders from across academic and industry sectors for essential career development advice and networking opportunities. Find out more about Career Roundtables here: https://www.keystonesymposia.org/diversity/career-development-initiatives

KEYSTONE SYMPOSIA THANKS OUR GIFT-IN-KIND MEDIA SPONSORS

Subscribe for Updates